Presbyopia
Conditions
Brief summary
A study to evaluate the efficacy, safety, and pharmacokinetics of pilocarpine HCl ophthalmic solution when administered bilaterally, once daily for 30 days in participants with presbyopia.
Interventions
Pilocarpine HCl ophthalmic solution 1.25%, one drop in each eye, once daily, for up to 30 days
DRUGVehicle
Vehicle, one drop in each eye, once daily, for up to 30 days.
Sponsors
CSPC Ouyi Pharmaceutical Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Intervention model description
For arm 1, patients received pilocarpine HCl ophthalmic solution 1.25%, one drop in each eye, once daily, for up to 30 days. For arm 2, patients received vehicle, one drop in each eye, once daily, for up to 30 days.
Eligibility
Sex/Gender
ALL
Age
40 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* 1 Participant must be 40 to 65 years of age inclusive, at the time of the screening visit; * 2 Emmetropes or non-emmetropes with best distance correction in the range of spherical -4.00 D to +2.00 D inclusively and cylinder ±2.00 D with photopic, high contrast CDVA of 20/25 or better in each eye at the screening and baseline visits; * 3 Mesopic, high contrast DCNVA of 20/40 to 20/100 in each eye at the screening and baseline visits; * 4 Photopic, high contrast, near visual acuity correctable to 20/40 or better in each eye at the screening and baseline visits; * 5 Dark adaptation pupil diameter between 4.0 mm and 8.0 mm in both eyes at the screening visit; * 6 Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
Exclusion criteria
* 1 Clinically significant disease state, in the opinion of the examining investigator or designee, in any body system; * 2 Known allergy or sensitivity to the study intervention or its components or other cholinergic agonist medications; * 3 Any active ocular inflammation within 30 days prior to the first use of the investigational drug; * 4 Current enrollment in an study or participation in such a study within 30 days prior to the first use of the investigational drug; * 5 Any clinical condition or previous surgery that might affect the absorption, distribution, biotransformation, or excretion; * 6 History of cataract surgery, phakic intraocular lens surgery, corneal refractive surgery, radial keratotomy, or any intraocular surgery; * 7 Presence of any ocular condition that, in the opinion of the investigator, could affect the safety of the participant or interpretation of efficacy parameters; * 8 Moderate to severe dry eye disease at the screening visit; * 9 Lens opacity in either eye that is determined to cause significant disturbance of the central visual axis at the screening visit; * 10 Diagnosis of any type of glaucoma or ocular hypertension; * 11 Female who have a positive pregnancy test during the screening period, lactating, or planning a pregnancy during the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Title: Percentage of Participants Gaining 3 Lines or More in Mesopic, High-contrast, Binocular Distance-Corrected Near Visual Acuity (DCNVA) at Day 30, Hour 3 | Baseline (Day 1) to Day 30 (Hour 3) |
Secondary
| Measure | Time frame |
|---|---|
| Area under the plasma concentration time curve from time zero to the last measurable concentration(AUC0-t) | Day 1 and Day 30 |
| Area under the plasma concentration-time curve from time zero to infinity(AUC0-inf) | Day 1 and Day 30 |
| Maximum plasma concentration(Cmax) | Day 1 and Day 30 |
| Incidence and frequency of adverse events (AE) and serious adverse events (SAE) etc. | Through study completion, an average of 60 days |
| Apparent Volume of Distribution During Terminal Phase (Vz/F) | Day 1 and Day 30 |
| Apparent Terminal Elimination Half-Life (T1/2) | Day 1 and Day 30 |
| Apparent total body clearance (CL/F) | Day 1 and Day 30 |
| Time to maximum plasma concentration (Tmax) | Day 1 and Day 30 |
Contacts
Primary ContactClinical Trials Information Group officer
Outcome results
None listed